Diamyd Medical AB (publ) — Investor Relations & Filings

Diamyd Medical is a clinical-stage company developing precision medicine therapies for the prevention and treatment of autoimmune diabetes, primarily Type 1 Diabetes. Its lead candidate, Diamyd®, is an antigen-specific immunotherapy based on the GAD65 protein. The therapy is designed to preserve the body's remaining insulin-producing capacity by re-educating the immune system to tolerate insulin-producing cells, thereby halting their autoimmune destruction. Diamyd® is being evaluated in late-stage clinical development, including the pivotal Phase III trial DIAGNODE-3, which utilizes a proprietary method of intralymphatic administration. The company is also establishing its own manufacturing facility for the GAD65 active pharmaceutical ingredient.